Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 2
1975 2
1976 2
1977 4
1978 3
1979 5
1980 3
1981 1
1982 2
1983 8
1984 4
1985 4
1986 3
1987 3
1988 1
1989 7
1990 2
1991 4
1992 5
1993 4
1994 8
1995 8
1996 6
1997 4
1998 1
1999 6
2000 3
2001 6
2002 8
2003 2
2004 2
2005 8
2006 4
2007 5
2008 4
2009 2
2010 4
2011 5
2012 3
2013 2
2014 4
2015 4
2016 4
2018 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Intracellular labile iron.
Breuer W, Shvartsman M, Cabantchik ZI. Breuer W, et al. Among authors: cabantchik zi. Int J Biochem Cell Biol. 2008;40(3):350-4. doi: 10.1016/j.biocel.2007.03.010. Epub 2007 Mar 19. Int J Biochem Cell Biol. 2008. PMID: 17451993 Review.
Erythrocyte membrane transport.
Cabantchik ZI. Cabantchik ZI. Novartis Found Symp. 1999;226:6-16; discussion 16-9. doi: 10.1002/9780470515730.ch2. Novartis Found Symp. 1999. PMID: 10645535 Review.
Iron as a therapeutic target for Parkinson's disease.
Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Moreau C, et al. Among authors: cabantchik zi. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Mov Disord. 2018. PMID: 29380903 Review. No abstract available.
The Labile Side of Iron Supplementation in CKD.
Slotki I, Cabantchik ZI. Slotki I, et al. Among authors: cabantchik zi. J Am Soc Nephrol. 2015 Nov;26(11):2612-9. doi: 10.1681/ASN.2015010052. Epub 2015 May 21. J Am Soc Nephrol. 2015. PMID: 25999405 Free PMC article. Review.
Intracellular and extracellular labile iron pools.
Cabantchik ZI, Kakhlon O, Epsztejn S, Zanninelli G, Breuer W. Cabantchik ZI, et al. Adv Exp Med Biol. 2002;509:55-75. doi: 10.1007/978-1-4615-0593-8_4. Adv Exp Med Biol. 2002. PMID: 12572989 Review. No abstract available.
LPI-labile plasma iron in iron overload.
Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. Cabantchik ZI, et al. Best Pract Res Clin Haematol. 2005 Jun;18(2):277-87. doi: 10.1016/j.beha.2004.10.003. Best Pract Res Clin Haematol. 2005. PMID: 15737890 Review.
Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V, Coates TD, Cabantchik ZI. Berdoukas V, et al. Among authors: cabantchik zi. Free Radic Biol Med. 2015 Nov;88(Pt A):3-9. doi: 10.1016/j.freeradbiomed.2015.07.019. Epub 2015 Jul 26. Free Radic Biol Med. 2015. PMID: 26216855 Review.
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC; FAIRPARK-II and FAIRALS-II studygroups. Devos D, et al. Among authors: cabantchik zi. J Neural Transm (Vienna). 2020 Feb;127(2):189-203. doi: 10.1007/s00702-019-02138-1. Epub 2020 Jan 7. J Neural Transm (Vienna). 2020. PMID: 31912279 Free article. Review.
Iron chelators: mode of action as antimalarials.
Cabantchik ZI, Glickstein H, Golenser J, Loyevsky M, Tsafack A. Cabantchik ZI, et al. Acta Haematol. 1996;95(1):70-7. doi: 10.1159/000203952. Acta Haematol. 1996. PMID: 8604590 Review.
169 results